GenScript Sets Up State-Of-Art Manufacturing Facility in Singapore to Strengthen Manufacturing Capability

10 February 2022 | Thursday | News

GenScript Biotech Corporation (Stock Code: 1548.HK), the world's leading life science research tools and services provider, today announced the opening of more than 30,000-square-feet facility for highly automated protein and gene preparation services.
Image Source : Public Domain

Image Source : Public Domain

The state-of-the-art site marks a significant expansion of the company's advanced  protein and gene platforms, and is designed to provide high quality, fast-turnaround on products  required for new vaccines and therapeutics development and innovations in life sciences. Supported by the Singapore’s Economic Development Board (EDB), the new production site will  support the Asia Pacific region and complements the current production sites in the United States  and China.  

The opening ceremony was held on a virtual setting inaugurated by Minister of State for Trade  and Industry, and Culture, Community and Youth, Mr Alvin Tan and accompanied by Senior  Vice President and Head, Healthcare, Singapore Economic Development Board (EDB), Ms Goh  Wan Yee. During the ceremony, GenScript and A*STAR Diagnostics Development Hub signed  on a memorandum of understanding (MoU) to explore the possibility of collaborations for the  purposes of building manufacturing capabilities in Singapore. 

The new manufacturing facility occupies over 30,000 square feet space at Solaris@Kallang  building. The cutting edge facility in Singapore features a high throughput platform and  proprietary technology of GenScript’s protein production to provide higher yield with a shorter  turnaround time. Together with an experienced scientific and commercial team, GenScript is  committed to provide tailored and top notch service to the region. The capacity of the new facility  could also be expanded to strengthen other business units to support cell and gene therapy and  vaccine development in the region. 

“This is a significant milestone for us as we strengthen our presence in the vibrant and innovative  ecosystem in Asia Pacific, Singapore. The new manufacturing facility will be a regional  innovation and excellence hub in Asia Pacific and increase productivity of custom protein  manufacturing,” said Mr. Johnson Wang, President of GenScript Asia Pacific Division. “With the new manufacturing plant, we will be able to foster stronger collaboration with partners, research  institutes and biopharmaceutical companies across the Asia Pacific region.” 

“Singapore the home to GenScript’s Asia Pacific headquarters, it is also a strategic location for us  to expand our manufacturing capability to support the fast growing biotechnology industry. With  the strong support from EDB, our new facility aims to be the center of a solid regional network to  

catalyze more collaboration, ultimately spurring more innovation and breakthrough life science.  This demonstrated GenScript’s commitment to build and develop the world leading enabling  platform in serving science,” said Dr. Ray Chen, President of Life Science Group, GenScript  Biotech Corporation. 

”GenScript’s decision to set up its new production site and business hub in Singapore is testament  to our robust manufacturing infrastructure, R&D and innovation ecosystem, strong base of  biotech talent, as well as our excellent connectivity to the Asia-Pacific region. We look forward  to working closely with GenScript to further expand its regional footprint, nurture local talent and 

drive better healthcare outcomes,” said Ms Goh Wan Yee, Senior Vice President and Head,  Healthcare, EDB. 

Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox


Forgot your password?



Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in